Company intelligence / Profile preview
BioAtla
San Diego, California, United Statesbioatla.com ↗
- Ownership
- Public · BCAB
- Development stage
- Other
01
Overview
BioAtla is developing multiple CAB-based therapeutics with lead candidates in Phase II/III trials. Mecbotamab vedotin (BA3011) is in Phase II/III for AXL-expressing tumors, Ozuriftamab vedotin (BA3021) is in Phase II for ROR2-expressing tumors, and BA3071 is in Phase II for CTLA-4 positive tumors as of 2024.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesAntibody-drug conjugates (ADCs)Cell-based therapeutics
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
Beyond the preview
Go deeper on BioAtla.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioAtla.